PDLI: PDL BioPharma, Inc. - Summary | Jitta

PDL BioPharma, Inc.

NASDAQ:PDLI

Notice
Stock data is unavailable or the company’s delisted.
Price
$2.47
Loss Chance
58.4%
0.73JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (0)
Recent Business Performance (11)
Financial Strength (53)
Return to Shareholders (22)
Competitive Advantage (11)
Jitta Signs
Share RepurchaseEvery Year
Revenue and EarningEarning loss detected in 2019
Operating MarginDeclined
Recent Business PerformanceEarning decline 22.44% in the last year
SG&A to SalesIncreasing Every Year
Key Stats
Jitta Score
Jitta Line
0.73
100.00%
2.22
137.59%
3.06
159.47%
Biotechnology
6.05
121.39%
2.03
99.83%
6.24
36.74%
COMPANY DESCRIPTION
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company’s patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.